228. Bronchiolitis obliterans
92 clinical trials,   125 drugs   (DrugBank: 34 drugs),   33 drug target genes,   152 drug target pathways

Searched query = "Bronchiolitis obliterans", "Obliterating bronchiolitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03603899
(ClinicalTrials.gov)
August 20204/10/2017Hp129 Xenon Imaging and BOS in Lung TransplantationImaging and Understanding Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplantation With Hyperpolarized 129Xenon MR Lung ImagingBronchiolitis ObliteransDrug: Hp 129XenonChildren's Hospital Medical Center, CincinnatiNULLRecruiting6 YearsN/AAll45Phase 1;Phase 2United States
2NCT04029636
(ClinicalTrials.gov)
August 20197/6/2019Hyperpolarized 129Xe MRI for the Assessment of BOS With Late Onset LONIPCHyperpolarized 129Xe Magnetic Resonance Imaging for the Early Detection of Bronchiolitis Obliterans Syndrome (BOS) and Other Late Onset Non-infectious Pulmonary Complications (LONIPCs) Following Hematopoietic Stem Cell TransplantationBronchiolitis ObliteransOther: Inhaled Hyperpolarized Xenon-129Hamilton Health Sciences CorporationNULLNot yet recruiting18 Years70 YearsAll45Canada